A Phase I, open-label study with escalating doses of intravenous PTK787/ZK 222584, a multi-VEGF receptor inhibitor, followed by multiple oral daily dosing to assess the absolute bioavailability of PTK787/ZK 222584 after single and multiple doses in advanced cancer patients

A Phase I, open-label study with escalating doses of intravenous PTK787/ZK 222584, a multi-VEGF receptor inhibitor, followed by multiple oral daily dosing to assess the absolute bioavailability of PTK787/ZK 222584 after single and multiple doses in advanced cancer patients

Bibliographic Details
Main Authors: Pavel, M, Schuppan, D, Jost, L, Kerr, D, Harris, A, Jalava, T, Masson, E, Palacay-Radona, M, Koehne, C
Format: Journal article
Published: 2005

Similar Items